0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Therapeutics |

Left ventricular assist devices reduced the risk for death and increased 1-year survival in chronic end-stage heart failure

Joseph S. Alpert, MD
[+] Article and Author Information

*See Glossary.

†Information provided by author.

‡Rose EA, Moskowitz AJ, Packer M, et al. Ann Thorac Surg. 1999; 67:723-30.

Sources of funding: In part, National Heart, Lung, and Blood Institute and Thoratec Corporation.

For correspondence: International Center for Health Outcomes and Innovation Research, Columbia University, New York, NY, USA.


Ann Intern Med. 2002;136(3):88. doi:10.7326/ACPJC-2002-136-3-088
Text Size: A A A

Question: In patients with chronic end-stage heart failure who are ineligible for a cardiac transplant, are left ventricular assist devices (LVADs) as effective as optimal medical management for long-term use?

Design: Randomized {allocation concealed*}†, unblinded,* controlled trial with 2-year follow-up.

Setting: 20 cardiac transplantation centers in the United States.

Patients: 129 patients (mean age 67 y, 80% men) who had chronic end-stage heart failure and contraindications for a heart transplant; a left ventricular ejection fraction of ≤ 25%; and symptoms of New York Heart Association (NYHA) class-IV heart failure for ≥ 60 days and a peak oxygen consumption of ≤ 14 mL/kg of body weight/min or a continued need for intravenous inotropic therapy because of symptomatic hypotension, decreasing renal function, or worsening pulmonary congestion. After 18 months of enrollment, entry criteria were relaxed to include patients with symptoms of NYHA class-III or -IV heart failure for ≥ 28 days and ≥ 14 days of support with an intra-aortic balloon pump or with a dependence on intravenous inotropic agents with 2 failed weaning attempts. Exclusion criteria are described elsewhere.‡ {Follow-up was 100%.}†

Intervention: Patients were allocated to an LVAD (n = 68) implanted into either a preperitoneal pocket or the peritoneal cavity or to optimal medical management (n = 61).

Main outcome measure: All-cause mortality for the 2-year observation period.

Main results: Analysis was by intention to treat and used Kaplan-Meier (KM) survival curves. The risk for death for the 2-year observation period was lower in the LVAD group than in the medical group (hazard ratio 0.52, 95% CI 0.34 to 0.78). 1-year survival was higher in the LVAD group than in the medi-cal group (KM estimates of survival 52% vs 25%, P = 0.002), but groups did not differ for 2-year survival (KM estimates of survival 23% vs 8%, P = 0.09).

Conclusions: In patients with chronic end-stage heart failure who are ineligible for a cardiac transplant, left ventricular assist devices (LVADs) reduced the risk for death more than did optimal medical management. LVADs increased 1-year survival, but groups did not differ for 2-year survival.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)